Loading...
Loading...
ANIK| Name | Value |
|---|---|
| Revenues | 43.0M |
| Cost of Revenue | 16.6M |
| Gross Profit | 26.3M |
| Operating Expense | 27.9M |
| Operating I/L | -1.6M |
| Other Income/Expense | -61.6M |
| Interest Income | 0.6M |
| Pretax | -63.2M |
| Income Tax Expense | -0.2M |
| Net Income/Loss | -63.0M |
Anika Therapeutics, Inc. specializes in early intervention orthopedic care, offering a range of products based on hyaluronic acid (HA) technology. Its portfolio includes OA pain management products such as Monovisc, Orthovisc, Cingal, and Hyvisc, designed to alleviate osteoarthritis pain. Additionally, the company provides bone preserving joint technology products, sports medicine soft tissue repair solutions, and orthopedic regenerative solutions. Anika Therapeutics also offers HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products.
